{"id":"W3208029444","doi":"10.1007/s12325-021-01898-1","title":"Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Actelion Pharmaceuticals; Seoul St. Mary's Hospital, Catholic University of Korea; Universitaire Ziekenhuizen Leuven, KU Leuven; Guangdong Provincial People's Hospital; Universität Wien; Peking Union Medical College; Karl-Franzens-Universität Graz; University of Ottawa; Medizinische Universität Graz; Peking Union Medical College Hospital; Changi General Hospital; Royal Adelaide Hospital; Samsung; Aarhus Universitetshospital; Shanghai Pulmonary Hospital; Centre Hospitalier Universitaire de Toulouse; Universität Greifswald; Seoul National University Hospital; Renji Hospital; Seoul National University; Catholic University of Korea; Aarhus Universitet; Jewish General Hospital; Medizinische Universität Wien; University of Alberta; Rigshospitalet","keywords":"Tolerability; Medicine; Discontinuation; Internal medicine; Clinical endpoint; Adverse effect; Placebo; Pulmonary hypertension; Clinical trial; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003111287,0.0006688515,0.001276076,0.0002687207,0.0001477586,0.0005870887,0.0003680375,0.0006659901,0.00319915],"category_scores_gemma":[0.00193261,0.0001611848,0.001596684,0.0002836369,0.0005339261,0.0007110034,0.0004135145,0.001043296,0.0003281413],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002702474,"about_ca_system_score_gemma":0.0003291015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001860847,"about_ca_topic_score_gemma":0.0003377401,"domain_scores_codex":[0.9991265,0.0005236685,0.0000791895,0.00009991044,0.00008889702,0.00008188664],"domain_scores_gemma":[0.9982175,0.000573834,0.0005698244,0.000185528,0.00007831721,0.0003749401],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.851191,0.008370395,0.01736823,0.001320974,0.002293243,0.0002093691,0.0002169504,0.000828924,0.008533065,0.0001059417,0.0009446994,0.1086172],"study_design_scores_gemma":[0.3778916,0.4751318,0.1381498,0.0001712343,0.002508822,0.0004969785,0.0001519424,0.0007417111,0.002434312,0.0002050518,0.002048789,0.00006795654],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951774,0.003303857,0.000135919,0.00009510176,0.00002495861,0.0001297421,0.0005373373,0.00001569075,0.0005800216],"genre_scores_gemma":[0.9959592,0.001373072,0.0003008824,0.0002714174,0.0001277985,0.0002543838,0.001134838,0.000005906962,0.0005725238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00319915,"threshold_uncertainty_score":0.01645428,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03548669979077369,"score_gpt":0.3073673866782115,"score_spread":0.2718806868874378,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}